

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 18, line 1, as follows:

After plasmid pGTPsMDgB obtained in Example 1 was digested with restriction enzyme MluI, and then obtained a blunt end with T4 DNA polymerase, which was followed by digestion with restriction enzyme XbaI to recover a fragment of 1.9 kb. Separately, pBluescript II (made by Toyobo Co., Ltd., hereinafter abbreviated as pBSKSII) was digested with restriction enzymes XbaI and SmaI. The resulting fragment was ligated with the 1.9 kb fragment obtained above using a ligase to give a plasmid. The resulting plasmid was digested with restriction enzymes EcoRI and Sall. The resulting fragment was ligated with the 550 bp fragment and the 615 bp fragment, both obtained by digestion of pNZ2929XM1 with restriction enzymes EcoRI and ~~SaH~~ EcoT22I and with restriction enzymes EcoT22I and Sall, respectively, using a ligase to construct a plasmid. The thus obtained plasmid was digested with restriction enzymes XbaI and Sall. The resulting 2.7 kb fragment was ligated with the 3.3 kb fragment obtained by digestion of pGTPsMDgB with restriction enzymes XbaI and Sall, using a ligase. Plasmid pGTPs40K-C ligating the TTM-1 gene at the N terminus thereof with the gB gene for Marek's disease virus at the C terminus thereof was thus obtained.

U.S. Patent Application Serial No. **09/147,052**
Amendment filed December 7, 2006
Reply to OA dated April 6, 2006

Please amend the paragraph beginning on page 18 line 24, as follows:

Finally, a fragment of 2.7 kb obtained by digestion of pGTPs40K-C with Sall and ~~XbaI~~
BamHI was ligated with a fragment of 9.5 kb obtained by digestion of plasmid pNZ1829R with Sall
and ~~XbaI~~ BamHI, using a ligase. The objective plasmid pNZ40K-C of 12.2 kb for recombination
was thus constructed.